

NET SALES AS OF 30 SEPTEMBER, 2016

Longjumeau; November 3, 2016

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of 30 September, 2016.

The PCAS Group had generated consolidated net sales of €134.1 million as of 30 September, 2016, representing growth of +8.5% compared to the same period during the previous financial year (+7.5% at a constant exchange rate).

<i>in millions of euros</i>	2016	2015	Growth in %	2016 At a constant exchange rate	Growth in %
Net sales as of 30 September	134.1	123.5	8.5%	132.8	7.5%
<i>Pharmaceutical Synthesis</i>	<i>88.2</i>	<i>80.1</i>	<i>10.1%</i>	<i>86.9</i>	<i>8.6%</i>
<i>Fine Specialty Chemicals</i>	<i>45.9</i>	<i>43.5</i>	<i>5.6%</i>	<i>45.8</i>	<i>5.5%</i>

Vincent Touraille, Chief Executive Officer of PCAS, explains: "Our business growth levelled off during the third quarter of 2016 compared to the same period during the previous financial year. Nevertheless, we are reasonably confident that we will achieve our objective of increasing our net sales in both Pharmaceutical Synthesis and Fine Specialty Chemicals, as well as improving results throughout 2016 compared to 2015."

Pharmaceutical Synthesis

The Pharmaceutical Synthesis business generated €88.2 million, up +10.1% on 2015 (+8.6% at a constant exchange rate), which was especially driven by the Exclusive activity.

Fine Specialty Chemicals

Net sales of Fine Specialty Chemicals amounted to €45.9 million, up 5.6% on 2015 (+5.5% at a constant exchange rate), with growth in both Performance Additives and Advanced Specialty Chemicals.



NEXT FINANCIAL DISCLOSURE:

Net sales 2016, January 31, 2017

ABOUT PCAS

PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 7% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers of a growing range of proprietary products and solutions in leading-edge segments and also

includes two very high-potential subsidiaries: Protéus in biotechnology and Enersens in high-performance insulation. PCAS generated net sales of €179.1 million in 2015 and employs close to 900 people in six countries.

To find out more about PCAS, visit: www.pcas.com



PCA
LISTED
EURONEXT

PCAS

NewCap

Vincent Touraille / Eric Moissenot
PCAS

Tel. : +33 1 69 79 61 32
www.pcas.com

Emmanuel Huynh / Louis-Victor Delouvrier
NewCap
Financial communication and Investor Relations

Tel. : +33 1 44 71 98 53
pcas@newcap.eu